[2] HAINAUT, PIERRE. [Advances in Cancer Research] Volume 77 || p53 and Human Cancer: The First Ten Thousand Mutations [J]. 1999, 81-137.[3] BAUGH E H, KE H, LEVINE A J, et al. Why are there hotspot mutations in
[2] HAINAUT, PIERRE. [Advances in Cancer Research] Volume 77 || p53 and Human Cancer: The First Ten Thousand Mutations [J]. 1999, 81-137. [3] BAUGH E H, KE H, LEVINE A J, et al. Why are there hotspot mutations in the...
HPV-negative penile squamous cell carcinoma: disruptive mutations in the TP53 gene are commonThe majority of penile squamous cell carcinomas is caused by transforming human papilloma virus (HPV) infection. The etiology of HPV-negative cancers is unclear, but TP53 mutations have been implicated. ...
GeneEdit Win 在生命科学的前沿浪潮中,一项划时代的突破正在照亮癌症治疗的未来。科学家们运用创新的碱基编辑技术,首次精准修复了关键肿瘤抑制基因TP53的突变,这一壮举将癌症治愈率推升至85%的新高度。这不仅是对抗疾病的巨大胜利,更是开启精准...
BAUGH E H, KE H, LEVINE A J, et al. Why are there hotspot mutations in the TP53 gene in...
Why is the TP53 gene observed to be the single most common mutation in human cancers? What properties of the gene and/or protein cause this? Cancers are otherwise very heterogeneous in both the nature and the frequency of mutations found in diverse tumors. 1New York University, New York,...
[4]https://dailynews.ascopubs.org/do/p53-most-frequently-muted-gene-cancer-but-can-we-target [5] https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tp53-gene [6]王凤,邓洪滨,邓立力.TP53、EGFR共突变对NSCLC治疗的影响及对预后预测作用的进展[J].中国肿瘤,2019,28(06):445-449. ...
[14] Hof J, Krentz S, van Schewick C, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011. 29(23): 3185-93. ...
tp53是一种肿瘤抑制基因(tumorsuppressorgene)。该基因对人体有保护作用,它时刻监控基因的完整性,一旦细胞dna遭到损伤,就能够阻止细胞进入dna合成期,抑制细胞的分裂和增殖,并且使损伤的dna修复,即使不能修复,也能够启动细胞的程序性死亡过程,防止细胞的恶性转化。研究表明,tp53基因rs12951053和rs2078486位点的多态性能够影...
In this regard, the present invention discloses importance of down-regulation of TP3 gene in multiple myeloma and its use as an independent progostic indicator of multiple myeloma. Additionally, the present invention also discloses novel-TP53 associated genes and demonstrates the clinical relevance ...